Last reviewed · How we verify
Tadalafil Pill
Tadalafil Pill is a Phosphodiesterase type 5 (PD5) inhibitor Small molecule drug developed by Santa Barbara Cottage Hospital. It is currently FDA-approved for Erectile dysfunction, Pulmonary arterial hypertension, Benign prostatic hyperplasia. Also known as: Adcirca.
Tadalafil inhibits phosphodiesterase type 5 (PD5) in the corpus cavernosum, increasing cyclic GMP levels to promote smooth muscle relaxation and improve blood flow.
Tadalafil inhibits phosphodiesterase type 5 (PD5) in the corpus cavernosum, increasing cyclic GMP levels to promote smooth muscle relaxation and improve blood flow. Used for Erectile dysfunction, Pulmonary arterial hypertension, Benign prostatic hyperplasia.
At a glance
| Generic name | Tadalafil Pill |
|---|---|
| Also known as | Adcirca |
| Sponsor | Santa Barbara Cottage Hospital |
| Drug class | Phosphodiesterase type 5 (PD5) inhibitor |
| Target | PD5 (phosphodiesterase type 5) |
| Modality | Small molecule |
| Therapeutic area | Urology, Cardiology, Pulmonology |
| Phase | FDA-approved |
Mechanism of action
By blocking PD5, tadalafil prevents the breakdown of cyclic GMP, allowing sustained smooth muscle relaxation in penile tissue and increased vasodilation. This mechanism also applies to pulmonary and systemic vasculature, explaining its use in pulmonary hypertension and benign prostatic hyperplasia. The drug's long half-life (17–21 hours) enables once-daily dosing for chronic conditions.
Approved indications
- Erectile dysfunction
- Pulmonary arterial hypertension
- Benign prostatic hyperplasia
- Pulmonary hypertension associated with chronic thromboembolic disease
Common side effects
- Headache
- Dyspepsia
- Back pain
- Myalgia
- Flushing
- Nasal congestion
- Vision abnormalities
Key clinical trials
- Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment (PHASE4)
- Effect of PDE5 Inhibition on Adipose Metabolism in Humans (PHASE2)
- Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients (PHASE2)
- Management of OAB in Female Patients . (NA)
- PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction (PHASE2)
- Low-intensity Shockwave Therapy (LiST) for the Treatment of Mild and Mild-to-moderate Vasculogenic Erectile Dysfunction (NA)
- The Use of Tadalafil in Confirmed COVID-19 Pneumonia. (PHASE4)
- Phosphodiesterase Inhibitors in Glaucoma Study (PhiGS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tadalafil Pill CI brief — competitive landscape report
- Tadalafil Pill updates RSS · CI watch RSS
- Santa Barbara Cottage Hospital portfolio CI
Frequently asked questions about Tadalafil Pill
What is Tadalafil Pill?
How does Tadalafil Pill work?
What is Tadalafil Pill used for?
Who makes Tadalafil Pill?
Is Tadalafil Pill also known as anything else?
What drug class is Tadalafil Pill in?
What development phase is Tadalafil Pill in?
What are the side effects of Tadalafil Pill?
What does Tadalafil Pill target?
Related
- Drug class: All Phosphodiesterase type 5 (PD5) inhibitor drugs
- Target: All drugs targeting PD5 (phosphodiesterase type 5)
- Manufacturer: Santa Barbara Cottage Hospital — full pipeline
- Therapeutic area: All drugs in Urology, Cardiology, Pulmonology
- Indication: Drugs for Erectile dysfunction
- Indication: Drugs for Pulmonary arterial hypertension
- Indication: Drugs for Benign prostatic hyperplasia
- Also known as: Adcirca
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing